Literature DB >> 12914397

[The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].

C Spitzweg1.   

Abstract

The sodium iodide symporter NIS) is an intrinsic plasma membrane protein that mediates the active transport of iodide in the thyroid gland and a number of extrathyrioidal tissues, in particular lactating mammary gland. Because of its crucial role in the ability of thyroid follicular cells to trap iodide of NIS opened an exciting and extensivenew field of thyroid-related research. Cloning and molecular characterization of NIS allowed investigation of its expression and regulation in thyroidal and nonthyroidal tissues, and its potential pathophysiological and therepeutic implications is benign and malignant thyroid diseases. In addition, NIS-mediated iodide accumulation allows diagnostic thyroid scintigraphy as well as effective therapeutic application of radio-iodide in benign and malignant thyroid disease. characterization and application of NIS as a novel therapeutic gene for cytoreductive gene therapy of extrathyroidal tumors, and the presence of high endogenous NIS expression in the majority of breast cancers further suggest a promising role of NIS in diagnosis and therapy of cancer outside the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12914397     DOI: 10.1007/s00108-003-0877-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  56 in total

Review 1.  Thyroid iodine transport.

Authors:  C Spitzweg; A E Heufelder; J C Morris
Journal:  Thyroid       Date:  2000-04       Impact factor: 6.568

2.  Cloning of the mouse sodium iodide symporter.

Authors:  L A Pinke; D S Dean; E R Bergert; C Spitzweg; C M Dutton; J C Morris
Journal:  Thyroid       Date:  2001-10       Impact factor: 6.568

3.  A novel peculiar mutation in the sodium/iodide symporter gene in spanish siblings with iodide transport defect.

Authors:  Shinji Kosugi; Hiroomi Okamoto; Aiko Tamada; F Sanchez-Franco
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

4.  Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer.

Authors:  M R Castro; E R Bergert; T G Beito; P C Roche; S C Ziesmer; S M Jhiang; J R Goellner; J C Morris
Journal:  J Endocrinol       Date:  1999-12       Impact factor: 4.286

5.  Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin.

Authors:  C Riedel; O Levy; N Carrasco
Journal:  J Biol Chem       Date:  2001-04-04       Impact factor: 5.157

6.  Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells.

Authors:  M R Castro; E R Bergert; T G Beito; B McIver; J R Goellner; J C Morris
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

7.  Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.

Authors:  Sean Carlin; Robert J Mairs; Phil Welsh; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2002-10       Impact factor: 2.408

8.  Effect of prolactin on sodium iodide symporter expression in mouse mammary gland explants.

Authors:  J A Rillema; T X Yu; S M Jhiang
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-10       Impact factor: 4.310

9.  Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study.

Authors:  B Caillou; F Troalen; E Baudin; M Talbot; S Filetti; M Schlumberger; J M Bidart
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

10.  Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene.

Authors:  Thomas Groot-Wassink; Eric O Aboagye; Matthias Glaser; Nicholas R Lemoine; Georges Vassaux
Journal:  Hum Gene Ther       Date:  2002-09-20       Impact factor: 5.695

View more
  2 in total

1.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

2.  Serum anti - TPO levels in benign and malignant breast tumors.

Authors:  Shruti Mohanty; Pragna Rao
Journal:  Indian J Clin Biochem       Date:  2009-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.